Uncategorized

The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve—driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats—the IVD market is…

IMV’s 2026 Diagnostic X-ray Market Outlook Report describes hospital trends in general radiography procedures, the installed base of fixed general X-ray equipment, DR and purchase plans and upgrades, capital equipment budgets, and site operations characteristics. Also included in this report is a summary of respondent’s departmental priorities and the factors affecting the future outlook for…

The 2026 SDi Global Assessment Datastream is only available to those who have purchased The 2026 Global Assessment Report: The Analytical and Life Science Instrumentation Industry.

Now in its thirteenth edition — Worldwide Market for Point-of-Care (POC) Diagnostic Tests analyzes the global POC diagnostics market with updated insights and forecasts through 2030.

Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 13th Edition delivers a comprehensive, forward-looking evaluation of one of the most strategically important segments of the in vitro diagnostics (IVD) industry.…

Report Description

How loyal are researchers to their antibody suppliers, and what drives them to switch? Which catalog antibody providers lead in customer satisfaction and retention, and where do gaps exist?

The 2026 edition of Customer Loyalty and Switching: Antibodies delivers a definitive read on where life science professionals stand today. Drawing on responses from…

The SDi Global Assessment Report provides detailed data on every major life science and analytical instrument technology in the industry, enabling you and your staff to make accurate evaluations and informed decisions. Numerous vendors, distributors and investors will reference this report over the coming years as the most comprehensive and accurate source of information on…

The global in vitro diagnostics (IVD) market is entering a period of measured but positive growth, shaped less by disruptive platform launches and more by strategic portfolio realignment, digital integration, and selective innovation. Kalorama Information’s 19th Edition of The Worldwide Market for In Vitro Diagnostic (IVD) Tests examines how industry participants are navigating competitive pressures, cost constraints,…

{
“@context”: “https://schema.org/”,
“@type”: [“Product”, “Report”],
“name”: “2026 Nuclear Medicine Market Outlook Report”,
“description”: “IMV’s 2026 Nuclear Medicine Market Outlook Report examines procedure volumes, SPECT/CT installed base, theranostics trends, radiopharmaceutical spending, and NM camera purchase plans. Based on a 2026 survey of 300 US NM administrators and technologists. 167 pages.”,
…

Immunoassays remain a foundational pillar of the in vitro diagnostics (IVD) landscape, underpinning a broad range of clinical testing applications despite the maturity of many platforms. Their continued relevance reflects both their versatility across disease areas and the steady pace of technological refinement that has sustained growth and clinical adoption over time. This Kalorama Information…

How has AI reshaped life science workflows in the past year? Which AI solutions have emerged as indispensable to researchers and which have fallen short? Do scientists genuinely trust AI-generated results, and how are those perceptions shifting? 

 

The 2026 edition of Perceptions of Artificial Intelligence in the Life Sciences delivers a definitive read on where life science professionals…

The Kalorama Molecular Diagnostics Quarterly Datastream is exclusively available to purchasers of our annual reports: Worldwide In Vitro Diagnostic (IVD) Tests, World Market for Molecular Diagnostics, or Molecular Point-of-Care (mPOC). This quarterly update covers markets detailed in these reports.

PET imaging has grown over the past two decades to become a mainstay in the diagnosis and management of cancer patients. While oncology scans continue to comprise the majority of PET scans, new radiopharmaceuticals offer the promise of increasing the efficacy of PET imaging for cardiology and neurology.

IMV’s 2026 PET Imaging Outlook Summary Report…